CDC7 kinase inhibitors and uses thereof
AssigneeSloan-Kettering Institute for Cancer Research
InventorsMark G. Frattini, Hakim Djaballah, Thomas J. Kelly
Life of this patent
Estimating the term…
Loading patent…
AssigneeSloan-Kettering Institute for Cancer Research
InventorsMark G. Frattini, Hakim Djaballah, Thomas J. Kelly
Estimating the term…
The invention provides compounds, methods, pharmaceutical compositions, and kits for the treatment of proliferative disorders such as cancer. In one aspect, the methods comprise compounds that inhibit the activity of protein kinases, such as cell division cycle (Cdc) kinase. In another aspect, the methods comprise compounds that inhibit Cdc7 and/or Dbf4 activity. In another aspect, the methods comprise compounds that exhibit anti-proliferative properties useful in treating diseases such as cancer. Compounds useful for any of the methods include compounds of the Formula (A) or (B): or pharmaceutically acceptable salts thereof. Exemplary compounds of Formula (A) or (B) include granaticin A, granaticin B, dihydrogranaticin A, dihydrogranaticin B, medermycin, and actinorhodin.
A method for treating cancer in a human subject in need thereof, comprising administering to the human subject a therapeutically effective amount of a compound of Formula (II):
A method for treating cancer in a human subject in need thereof comprising administering to the human subject a therapeutically effective amount of a compound of the Formula (II):
Dependencies are inferred from the claim text.